BidaskClub cut shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a buy rating to a hold rating in a research note published on Thursday, BidAskClub reports.

Several other research firms also recently issued reports on ACHN. Barclays downgraded shares of Achillion Pharmaceuticals from an equal weight rating to an underweight rating and decreased their price objective for the stock from $5.00 to $2.50 in a report on Friday, May 3rd. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Monday. Finally, William Blair reissued an outperform rating on shares of Achillion Pharmaceuticals in a report on Thursday, March 7th. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company. The company has an average rating of Hold and a consensus target price of $2.50.

NASDAQ ACHN opened at $2.81 on Thursday. The firm has a market cap of $398.14 million, a P/E ratio of -5.51 and a beta of 2.41. Achillion Pharmaceuticals has a 1 year low of $1.29 and a 1 year high of $3.98.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). On average, analysts anticipate that Achillion Pharmaceuticals will post -0.59 earnings per share for the current year.

Institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in Achillion Pharmaceuticals in the 1st quarter valued at $33,000. Parametric Portfolio Associates LLC boosted its holdings in Achillion Pharmaceuticals by 21.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 21,014 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 3,700 shares during the period. Acadian Asset Management LLC bought a new stake in Achillion Pharmaceuticals in the 4th quarter valued at $41,000. Meeder Asset Management Inc. boosted its holdings in Achillion Pharmaceuticals by 107.3% in the 4th quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 13,706 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its holdings in Achillion Pharmaceuticals by 934.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 31,444 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 28,404 shares during the period. 77.65% of the stock is owned by hedge funds and other institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Recommended Story: What are the benefits of buying treasury bonds?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.